Pictured are Annabel Murphy (aged 8) who has cystic fibrosis with Prof Paul McNally, RCSI Associate Professor of Paediatrics, at the launch of a new €3 million study, led by the RCSI, to investigate the real-world effects of a new cystic fibrosis medication. Researchers at the RCSI University of Medicine and Health Sciences are leading the international research project, called RECOVER, to look at how a new triple combination cystic fibrosis drug, Kaftrio, will affect people in their day-to-day lives. The project has been awarded €2.85 million from the Cystic Fibrosis Foundation (US), €112,000 from the Cystic Fibrosis Trust (UK), and €100,000 from Cystic Fibrosis Ireland.
Related Sites
Sign In
NOTE: By submitting this form and registering with us, you are providing us with permission to store your personal data and the record of your registration. In addition, registration with the Medical Independent includes granting consent for the delivery of that additional professional content and targeted ads, and the cookies required to deliver same. View our Privacy Policy and Cookie Notice for further details.
You can opt out at anytime by visiting our cookie policy page.
In line with the provisions of the GDPR, the provision of your personal data is a requirement necessary to enter into a contract. We must advise you at the point of collecting your personal data that it is a required field, and the consequences of not providing the personal data is that we cannot provide this service to you.
Don't have an account? Subscribe
Leave a Reply
You must be logged in to post a comment.